MDxHealth S.A. operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MDxHealth S.A. with three other
miscellaneous service companies in Europe:
Kiadis Pharma NV
of NETHERLANDS
(2020
sales of 17.50 million Euros [US$21.21 million]
),
Bioinvent International AB
of SWEDEN
(147.37 million Swedish Kronor [US$17.66 million]
of which 52%
was Revenue from collaboration agreements as), and
Tissue Regenix Group PLC
which is
based in UNITED KINGDOM
(£12.83 million [US$17.89 million]
).
Sales Analysis.
MDxHealth S.A. reported sales of 16.09 million Euro (US$19.50 million)
for the
year ending
December of 2020.
This
represents
an
increase of 52.6%
versus 2019, when the company's sales were 10.54 million Euro.
Despite this increase, sales are still
well
below the level achieved in 2018, when MDxHealth S.A.
reported sales of 24.10 million Euro.
The sales level in 2020 was fairly close to the level five years ago: in 2015, MDxHealth S.A. had sales
of 15.99 million Euro.